--- title: "John Hess becomes sole director and officer of KalVista; Multiple directors resign" type: "News" locale: "en" url: "https://longbridge.com/en/news/289513559.md" description: "KalVista Pharmaceuticals announced that eight directors resigned and John Hess became the sole director and an officer (President and Secretary) following a merger. Executive compensation agreements, including transaction bonuses and gross-up provisions for potential excise taxes, were established for several executives effective at the time of the merger." datetime: "2026-06-11T20:53:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289513559.md) - [en](https://longbridge.com/en/news/289513559.md) - [zh-HK](https://longbridge.com/zh-HK/news/289513559.md) generator: "portal-rs" --- # John Hess becomes sole director and officer of KalVista; Multiple directors resign **KalVista saw eight directors resign and John Hess become the company's sole director and an officer at the Effective Time, with related executive compensation agreements for several executives.** Individual Brian J. G. Pereira Benjamin L. Palleiko William Fairey Laurence Reid Bethany Sensenig Nancy Stuart Patrick Treanor Edward W. Unkart John Hess Brian Piekos Paul Audhya Role Director Director; Chief Executive Officer Director Director; PhD Director Director Director Director Sole Director; Officer (President and Secretary of Purchaser became officer of the Company) Chief Financial Officer Chief Medical Officer Type of Change Resigned Resigned (director) / Transaction bonus agreement Resigned Resigned Resigned Resigned Resigned Resigned Appointed (became sole director and officer) Entered into Gross-Up Agreement; Transaction bonus agreement Transaction bonus agreement Effective Date Effective Time Resigned: Effective Time; Bonus agreement: on or within 60 days of Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Gross-Up: June 11, 2026; Bonus agreement: on or within 60 days of Effective Time Transaction bonus agreement: on or within 60 days of Effective Time Reason In connection with the Merger In connection with the Merger; bonus tied to Merger In connection with the Merger In connection with the Merger In connection with the Merger In connection with the Merger In connection with the Merger In connection with the Merger In connection with the Merger Gross-Up to cover potential excise tax on parachute payments; Merger-related Merger-related Replacement Info John Hess became sole director Not disclosed (director resignation); remains referenced as CEO for bonus John Hess became sole director John Hess became sole director John Hess became sole director John Hess became sole director John Hess became sole director John Hess became sole director N/A (sole director) Not disclosed Not disclosed Background Details Not disclosed Named as CEO and Executive for Transaction Bonus Agreement Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Was President and Secretary of Purchaser prior to Effective Time; previously sole director of Purchaser (details in referenced Schedule I) Gross-Up calculation depends on Code Sections 280G and 4999; amount unknown Transaction bonus amount specified Board/Committee Role Changes Resigned from board and all committees Resigned from board and all committees Resigned from board and all committees Resigned from board and all committees Resigned from board and all committees Resigned from board and all committees Resigned from board and all committees Resigned from board and all committees Became sole director of the Company Not disclosed Not disclosed Original SEC Filing: KalVista Pharmaceuticals, Inc. \[ KALV \] - 8-K - Jun. 11, 2026 ### Related Stocks - [KALV.US](https://longbridge.com/en/quote/KALV.US.md) ## Related News & Research - [KalVista Pharmaceuticals Announced Transfer or Voluntary Withdrawal of Listing](https://longbridge.com/en/news/289513582.md) - [KalVista Pharmaceuticals (KALV) Gets a Buy from Stifel Nicolaus](https://longbridge.com/en/news/280919206.md) - [BSEM: Expanding hospital market access and clinical portfolio drive growth and profitability](https://longbridge.com/en/news/296363786.md) - [Why Is Ocular Therapeutix Stock Gaining Monday?](https://longbridge.com/en/news/296134890.md) - [Ocular Therapeutix Earns Buy Rating as Axpaxli Differentiation and LUGANO TKI Data Bolster Confidence in Lead Asset](https://longbridge.com/en/news/296129081.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**